Related Experiment Video
Updated: Mar 12, 2026
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Heart transplantation in adult congenital heart disease
Insights
Heart failure (HF) in adult congenital heart disease (ACHD) requires structural interventions, unlike acquired HF. Heart transplantation is a viable option for end-stage ACHD patients, with outcomes improving through specialized care and risk stratification.
Area of Science:
- Cardiology
- Adult Congenital Heart Disease
- Heart Failure Management
Background:
- Heart failure (HF) in adult congenital heart disease (ACHD) presents unique challenges distinct from acquired heart disease.
- Pharmacological strategies, standard for acquired HF, are less central in ACHD-related HF, which relies more on structural interventions.
Purpose of the Study:
- To review current diagnostic and therapeutic strategies for advanced HF in ACHD patients.
- To examine indications, contraindications, and outcomes of heart transplantation in ACHD.
- To highlight opportunities for improving outcomes in ACHD-related HF.
Main Methods:
- Review of current approaches to diagnosing and treating advanced HF in ACHD.
- Analysis of heart transplantation indications, contraindications, and clinical outcomes in ACHD.
- Identification of key areas for outcome improvement in ACHD-related HF.
Main Results:
- Heart transplantation is an effective life-extending treatment for selected ACHD patients with end-stage cardiac disease.
- ACHD patients represent a growing proportion of adult heart transplant recipients.
- Opportunities for improved outcomes include earlier recognition, risk awareness, collaborative care, expert surgical planning, tailored immunosuppression, and ACHD-specific risk scores.
Conclusions:
- Heart transplantation is a crucial option for end-stage ACHD patients.
- Multidisciplinary collaboration and ACHD-specific approaches are vital for optimizing HF management and transplant outcomes.
- Earlier referral and risk stratification can significantly improve survival and quality of life.
Abstract:
Heart failure (HF) in adult congenital heart disease (ACHD) is vastly different to that observed in acquired heart disease. Unlike acquired HF in which pharmacological strategies are the cornerstone for protecting and improving ventricular function, ACHD-related HF relies heavily upon structural and other interventions to achieve these aims. patients with ACHD constitute a small percentage of the total adult heart transplant population (∼3%), although the number of ACHD heart transplant recipients is growing rapidly with a 40% increase over the last two decades. The worldwide experience to date has confirmed heart transplantation as an effective life-extending treatment option in carefully selected patients with ACHD with end-stage cardiac disease. Opportunities for improving outcomes in patients with ACHD-related HF include (i) earlier recognition and referral to centres with combined expertise in ACHD and HF, (ii) increased awareness of arrhythmia and sudden cardiac death risk in this population, (iii) greater collaboration between HF and ACHD specialists at the time of heart transplant assessment, (iv) expert surgical planning to reduce ischaemic time and bleeding risk at the time of transplant, (v) tailored immunosuppression in the post-transplant period and (vi) development and validation of ACHD-specific risk scores to predict mortality and guide patient selection. The purpose of this article is to review current approaches to diagnosing and treating advanced HF in patients with ACHD including indications, contraindications and clinical outcomes after heart transplantation.
